Could Low-Dose Naltrexone be an Effective Treatment for Hailey-Hailey Disease?
Although originally described by the Hailey brothers in 1939, Hailey-Hailey disease (HHD), or familial benign chronic pemphigus, still does not have an established treatment method. Recent testimonial and anecdotal evidence suggest low-dose naltrexone (LDN) as an effective treatment for HHD. Naltrexone was originally approved by the US Food and Drug Administration in 1984 for the treatment of alcohol and opiate addiction. In lower doses (4.5 mg or less rather than 50 mg), naltrexone is being used to treat many diseases; however, there are no published studies on its long-term efficacy or for the treatment of HHD.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).